Staidson (Beijing) BioPharmaceuticals Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Staidson (Beijing) BioPharmaceuticals Co., Ltd. carries a market capitalization of 12.11B, placing it among publicly traded companies globally. Its enterprise value stands at -150.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.11B |
| Enterprise Value | -150.22M |
Share Statistics
Staidson (Beijing) BioPharmaceuticals Co., Ltd. currently has 477.77M shares outstanding.
| Shares Outstanding | 477.77M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Staidson (Beijing) BioPharmaceuticals Co., Ltd. maintains a current ratio of 2.58, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.91, indicating elevated leverage, while an interest coverage ratio of -86.59 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.58 |
| Quick Ratio | 1.49 |
| Debt / Equity | 1.91 |
| Debt / EBITDA | -0.33 |
| Interest Coverage | -86.59 |
Financial Efficiency
| Return on Equity (ROE) | -131.14 |
| Return on Assets (ROA) | -13.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.88 |
Taxes
| Income Tax | 113.41M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s stock has declined approximately -42.54306% over the past 52 weeks. The 50-day moving average sits at 24.81, while the 200-day moving average is 28.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | -42.54306% |
| 50-Day Moving Average | 24.81 |
| 200-Day Moving Average | 28.61 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -61.40M, while operating income came in at -61.40M.
| Revenue | 268.02M |
| Gross Profit | 210.08M |
| Operating Income | -61.40M |
| Pretax Income | -60.05M |
| Net Income | -166.06M |
| EBITDA | -61.40M |
| EBIT | -61.40M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Staidson (Beijing) BioPharmaceuticals Co., Ltd. holds 173.17M in cash and equivalents against 20.07M in total debt, resulting in a net debt position of -153.15M. Total book value stands at 34.36M, with working capital of 183.58M providing operational flexibility.
| Cash & Cash Equivalents | 173.17M |
| Total Debt | 20.07M |
| Net Debt | -153.15M |
| Equity (Book Value) | 34.36M |
| Book Value Per Share | N/A |
| Working Capital | 183.58M |
Cash Flow
| Operating Cash Flow | N/A |
| Capital Expenditures | -20.47M |
| Free Cash Flow | -20.47M |
| FCF Per Share | N/A |
Margins
Staidson (Beijing) BioPharmaceuticals Co., Ltd. operates with a gross margin of 78.38, reflecting its pricing power and cost economics. The operating margin of -22.91 and net profit margin of -61.96 provide insight into operational efficiency.
| Gross Margin | 78.38 |
| Operating Margin | -22.91 |
| Pretax Margin | -22.41 |
| Profit Margin | -61.96 |
| EBITDA Margin | -22.91 |
Dividends & Yields
The company's payout ratio of -0.02 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -0.02 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Stock Splits
Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s most recent stock split took place on May 5, 2016 with a 1000:1399 split ratio.
| Last Split Date | 5/5/2016 |
| Split Ratio | 1000:1399 |
Scores
Staidson (Beijing) BioPharmaceuticals Co., Ltd. posts an Altman Z-Score of -0.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.32 |